IBX was oversold in my view last week as a result of disappointing trial results (no takers for the trial). IBX management should be learning from this and devising new incentives to acquire patients willing to trial. When they do, the SP should return to it's recent high of 21c and potentially higher.
Will take some patience but for those with some spare $ now is a good time to put a little away.
Riesling _________________
Imagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to find and detect cancer.
